Recent advances in understanding Epstein-Barr virus

F1000Research

Volumn 6, Issue , 2017, Pages

  Luftig, Micah A ^a   Stanfield, Brent A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

EBV; Gastric cancer; Herpes simplex virus; Herpesvirus

Indexed keywords

ASYMPTOMATIC DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; EPITHELIUM; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION; HIGH THROUGHPUT SEQUENCING; HOST PATHOGEN INTERACTION; HUMAN; LYMPHOID TISSUE; MALIGNANT NEOPLASM; MONONUCLEOSIS; NEXT GENERATION SEQUENCING; NONHUMAN; PATHOGENESIS; REVIEW; STOMACH CANCER; STRAIN DIFFERENCE;

EID: 85017100234     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.10591.1     Document Type: Review

References (77)

1. Knipe DM Howley PM: Fields virology.6th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins Health.2013; 2 volumes. Reference Source
2. Epstein MA Achong BG Barr YM: Virus Particles In Cultured Lymphoblasts From Burkitt's Lymphoma. Lancet. 1964;1(7335):702-3. 14107961 10.1016/S0140-6736(64)91524-7
3. Henle W Diehl V Kohn G: Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science. 1967;157(3792):1064-5. 6036237 10.1126/science.157.3792.1064
4. Pope JH Horne MK Scott W: Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer. 1968;3(6):857-66. 4894385 10.1002/ijc.2910030619
5. Khan G Hashim MJ: Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010. Infect Agent Cancer. 2014;9(1):38. 25473414 10.1186/1750-9378-9-38 4253616 F1000 Recommendation
6. Miller N Hutt-Fletcher LM: Epstein-Barr virus enters B cells and epithelial cells by different routes. J Virol. 1992;66(6):3409-14. 1316456 241121
7. Nemerow GR Cooper NR: Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process. Virology. 1984;132(1):186-98. 6320532
8. Mullen MM Haan KM Longnecker R: Structure of the Epstein-Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1. Mol Cell. 2002;9(2):375-85. 11864610 10.1016/S1097-2765(02)00465-3
9. Arredouani MS Bhasin MK Sage DR: Analysis of host gene expression changes reveals distinct roles for the cytoplasmic domain of the Epstein-Barr virus receptor/CD21 in B-cell maturation, activation, and initiation of virus infection. J Virol. 2014;88(10):5559-77. 24600013 10.1128/JVI.03099-13 4019091 F1000 Recommendation
10. Tsai K Thikmyanova N Wojcechowskyj JA: EBV tegument protein BNRF1 disrupts DAXX-ATRX to activate viral early gene transcription. PLoS Pathog. 2011;7(11):e1002376. 22102817 10.1371/journal.ppat.1002376 3213115
11. Xue Y Gibbons R Yan Z: The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. Proc Natl Acad Sci U S A. 2003;100(19):10635-40. 12953102 10.1073/pnas.1937626100 196856
12. Shaw JE Levinger LF Carter CW Jr: Nucleosomal structure of Epstein-Barr virus DNA in transformed cell lines. J Virol. 1979;29(2):657-65. 219253 353198
13. Jochum S Ruiss R Moosmann A: RNAs in Epstein-Barr virions control early steps of infection. Proc Natl Acad Sci U S A. 2012;109(21):E1396-404. 22543160 10.1073/pnas.1115906109 3361417 F1000 Recommendation
14. Albanese M Tagawa T Bouvet M: Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8 + T cells. Proc Natl Acad Sci U S A. 2016;113(42):E6467-E6475. 27698133 10.1073/pnas.1605884113 5081573 F1000 Recommendation
15. Tagawa T Albanese M Bouvet M: Epstein-Barr viral miRNAs inhibit antiviral CD4 + T cell responses targeting IL-12 and peptide processing. J Exp Med. 2016;213(10):2065-80. 27621419 10.1084/jem.20160248 5030804 F1000 Recommendation
16. Kalla M Schmeinck A Bergbauer M: AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc Natl Acad Sci U S A. 2010;107(2):850-5. 20080764 10.1073/pnas.0911948107 2818922 F1000 Recommendation
17. Wen W Iwakiri D Yamamoto K: Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes. J Virol. 2007;81(2):1037-42. 17079287 10.1128/JVI.01416-06 1797481
18. Halder S Murakami M Verma SC: Early events associated with infection of Epstein-Barr virus infection of primary B-cells. PLoS One. 2009;4(9):e7214. 19784370 10.1371/journal.pone.0007214 2746279
19. Zhang Q Gutsch D Kenney S: Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol. 1994;14(3):1929-38. 8114724 10.1128/MCB.14.3.1929 358551
20. Altmann M Hammerschmidt W: Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol. 2005;3(12):e404. 16277553 10.1371/journal.pbio.0030404 1283332
21. Kelly GL Long HM Stylianou J: An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog. 2009;5(3):e1000341. 19283066 10.1371/journal.ppat.1000341 2652661
22. Feederle R Linnstaedt SD Bannert H: A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus. PLoS Pathog. 2011;7(2):e1001294. 21379335 10.1371/journal.ppat.1001294 3040666
23. Seto E Moosmann A Grömminge S: Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog. 2010;6(8):e1001063. 20808852 10.1371/journal.ppat.1001063 2924374
24. Xing L Kieff E: Epstein-Barr virus BHRF1 micro- and stable RNAs during latency III and after induction of replication. J Virol. 2007;81(18):9967-75. 17626073 10.1128/JVI.02244-06 2045418
25. Nikitin PA Yan CM Forte E: An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe. 2010;8(6):510-22. 21147465 10.1016/j.chom.2010.11.004 3049316
26. Price AM Tourigny JP Forte E: Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-κB activation. J Virol. 2012;86(20):11096-106. 22855490 10.1128/JVI.01069-12 3457162
27. Klein E Nagy N Rasul AE: EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1: Type IIb latency. Oncoimmunology. 2013;2(2):e23035. 23526738 10.4161/onci.23035 3601171
28. Nikitin PA Price AM McFadden K: Mitogen-induced B-cell proliferation activates Chk2-dependent G1/S cell cycle arrest. PLoS One. 2014;9(1):e87299. 24498068 10.1371/journal.pone.0087299 3907503
29. God JM Cameron C Figueroa J: Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors. J Immunol. 2015;194(4):1434-45. 25595783 10.4049/jimmunol.1402382 4323931 F1000 Recommendation
30. Staege MS Lee SP Frisan T: MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells. Proc Natl Acad Sci U S A. 2002;99(7):4550-5. 11917131 10.1073/pnas.072495599 123685
31. Tugizov SM Berline JW Palefsky JM: Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med. 2003;9(3):307-14. 12592401 10.1038/nm830 F1000 Recommendation
32. Shibata D Weiss LM: Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol. 1992;140(4):769-74. 1314023 1886378
33. Fang WT Huang KH Lan YT: Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers. Oncotarget. 2016;7(5):6201-20. 26701847 10.18632/oncotarget.6641 4868750 F1000 Recommendation
34. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202-9. 25079317 10.1038/nature13480 4170219 F1000 Recommendation
35. Blank C Mackensen A: Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56(5):739-45. 17195077 10.1007/s00262-006-0272-1
36. Strong MJ Laskow T Nakhoul H: Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas. J Virol. 2015;89(19):10110-4. 26178981 10.1128/JVI.01110-15 4577887 F1000 Recommendation
37. Camargo MC Kim W Chiaravalli AM: Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut. 2014;63(2):236-43. 23580779 10.1136/gutjnl-2013-304531 4384434 F1000 Recommendation
38. Marquitz AR Mathur A Shair KH: Infection of Epstein-Barr virus in a gastric carcinoma cell line induces anchorage independence and global changes in gene expression. Proc Natl Acad Sci U S A. 2012;109(24):9593-8. 22647604 10.1073/pnas.1202910109 3386136
39. Raab-Traub N Dambaugh T Kieff E: DNA of Epstein-Barr virus VIII: B95-8, the previous prototype, is an unusual deletion derivative. Cell. 1980;22(1 Pt 1):257-67. 6253079 10.1016/0092-8674(80)90173-7
40. Edwards RH Marquitz AR Raab-Traub N: Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing. J Virol. 2008;82(8):9094-106. 18614630 10.1128/JVI.00785-08 2546912
41. Kanda T Furuse Y Oshitani H: Highly Efficient CRISPR/Cas9-Mediated Cloning and Functional Characterization of Gastric Cancer-Derived Epstein-Barr Virus Strains. J Virol. 2016;90(9):4383-93. 26889033 10.1128/JVI.00060-16 4836357 F1000 Recommendation
42. Tzellos S Correia PB Karstegl CE: A single amino acid in EBNA-2 determines superior B lymphoblastoid cell line growth maintenance by Epstein-Barr virus type 1 EBNA-2. J Virol. 2014;88(16):8743-53. 24850736 10.1128/JVI.01000-14 4136291 F1000 Recommendation
43. Palser AL Grayson NE White RE: Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection. J Virol. 2015;89(10):5222-37. 25787276 10.1128/JVI.03614-14 4442510 F1000 Recommendation
44. Tsai MH Raykova A Klinke O: Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas. Cell Rep. 2013;5(2):458-70. 24120866 10.1016/j.celrep.2013.09.012 F1000 Recommendation
45. Midgley RS Bell AI Yao QY: HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences. J Virol. 2003;77(21):11507-16. 14557636 10.1128/JVI.77.21.11507-11516.2003 229266
46. White RE Ramer PC Naresh KN: EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest. 2012;122(4):1487-502. 22406538 10.1172/JCI58092 3314448
47. Coleman CB Wohlford EM Smith NA: Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines. J Virol. 2015;89(4):2301-12. 25505080 10.1128/JVI.03001-14 4338898 F1000 Recommendation
48. Kimura H Hoshino Y Kanegane H: Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98(2):280-6. 11435294 10.1182/blood.V98.2.280
49. Calattini S Sereti I Scheinberg P: Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH. Blood. 2010;116(22):4546-59. 20699441 10.1182/blood-2010-05-285452 2996115
50. Kimura H Ito Y Kawabe S: EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012;119(3):673-86. 22096243 10.1182/blood-2011-10-381921
51. Fox CP Shannon-Lowe C Gothard P: Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. Clin Infect Dis. 2010;51(1):66-9. 20504238 10.1086/653424
52. Kimura H Morishima T Kanegane H: Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis. 2003;187(4):527-33. 12599068 10.1086/367988
53. Cohen JI Jaffe ES Dale JK: Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011;117(22):5835-49. 21454450 10.1182/blood-2010-11-316745 3112034
54. Mosier DE Gulizia RJ Baird SM: Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature. 1988;335(6187):256-9. 2970594 10.1038/335256a0
55. Fujiwara S Matsuda G Imadome K: Humanized mouse models of epstein-barr virus infection and associated diseases. Pathogens. 2013;2(1):153-76. 25436886 10.3390/pathogens2010153 4235711
56. Fujiwara S Imadome K Takei M: Modeling EBV infection and pathogenesis in new-generation humanized mice. Exp Mol Med. 2015;47(1):e135. 25613732 10.1038/emm.2014.88 4314584
57. Ishikawa F Yasukawa M Lyons B: Development of functional human blood and immune systems in NOD/SCID/IL2 receptor (gamma) chain null mice. Blood. 2005;106(5):1565-73. 15920010 10.1182/blood-2005-02-0516 1895228
58. Shultz LD Saito Y Najima Y: Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma null humanized mice. Proc Natl Acad Sci U S A. 2010;107(29):13022-7. 20615947 10.1073/pnas.1000475107 2919921
59. Chijioke O Müller A Feederle R: Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. Cell Rep. 2013;5(6):1489-98. 24360958 10.1016/j.celrep.2013.11.041 3895765 F1000 Recommendation
60. Melkus MW Estes JD Padgett-Thomas A: Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med. 2006;12(11):1316-22. 17057712 10.1038/nm1431 F1000 Recommendation
61. Yajima M Imadome K Nakagawa A: A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis. 2008;198(5):673-82. 18627269 10.1086/590502
62. Sato K Misawa N Nie C: A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. Blood. 2011;117(21):5663-73. 21467545 10.1182/blood-2010-09-305979
63. Toussirot E Roudier J: Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: an update. Joint Bone Spine. 2007;74(5):418-26. 17625943 10.1016/j.jbspin.2007.05.001
64. Erre GL Mameli G Cossu D: Increased Epstein-Barr Virus DNA Load and Antibodies Against EBNA1 and EA in Sardinian Patients with Rheumatoid Arthritis. Viral Immunol. 2015;28(7):385-90. 26083265 10.1089/vim.2015.0035 F1000 Recommendation
65. Mahabadi M Faghihiloo E Alishiri GH: Detection of Epstein-Barr virus in synovial fluid of rheumatoid arthritis patients. Electron Physician. 2016;8(3):2181-6. 27123228 10.19082/2181 4844486 F1000 Recommendation
66. Kuwana Y Takei M Yajima M: Epstein-Barr virus induces erosive arthritis in humanized mice. PLoS One. 2011;6(10):e26630. 22028930 10.1371/journal.pone.0026630 3197576
67. Ma SD Xu X Jones R: PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model. PLoS Pathog. 2016;12(5):e1005642. 27186886 10.1371/journal.ppat.1005642 4871349
68. Landtwing V Raykova A Pezzino G: Cognate HLA absence in trans diminishes human NK cell education. J Clin Invest. 2016;126(10):3772-82. 27571408 10.1172/JCI86923 5096830
69. Lin X Tsai MH Shumilov A: The Epstein-Barr Virus BART miRNA Cluster of the M81 Strain Modulates Multiple Functions in Primary B Cells. PLoS Pathog. 2015;11(12):e1005344. 26694854 10.1371/journal.ppat.1005344 4691206
70. Whitehurst CB Li G Montgomery SA: Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice. mBio. 2015;6(5):e01574-15. 26489865 10.1128/mBio.01574-15 4620474
71. Lee EK Joo EH Song K: Effects of lymphocyte profile on development of EBV-induced lymphoma subtypes in humanized mice. Proc Natl Acad Sci U S A. 2015;112(42):13081-6. 26438862 10.1073/pnas.1407075112 4620895 F1000 Recommendation
72. Gregorovic G Boulden EA Bosshard R: Epstein-Barr Viruses (EBVs) Deficient in EBV-Encoded RNAs Have Higher Levels of Latent Membrane Protein 2 RNA Expression in Lymphoblastoid Cell Lines and Efficiently Establish Persistent Infections in Humanized Mice. J Virol. 2015;89(22):11711-4. 26339045 10.1128/JVI.01873-15 4645642 F1000 Recommendation
73. Chijioke O Marcenaro E Moretta A: Role of the 2B4 Receptor in CD8 + T-Cell-Dependent Immune Control of Epstein-Barr Virus Infection in Mice With Reconstituted Human Immune System Components. J Infect Dis. 2015;212(5):803-7. 25722295 10.1093/infdis/jiv114 F1000 Recommendation
74. Ma SD Xu X Plowshay J: LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis. J Clin Invest. 2015;125(1):304-15. 25485679 10.1172/JCI76357 4382240 F1000 Recommendation
75. Antsiferova O Muller A Ramer PC: Adoptive transfer of EBV specific CD8 + T cell clones can transiently control EBV infection in humanized mice. PLoS Pathog. 2014;10(8):e1004333. 25165855 10.1371/journal.ppat.1004333 4148450 F1000 Recommendation
76. Xiang Z Liu Y Zheng J: Targeted activation of human Vγ9Vδ2-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease. Cancer Cell. 2014;26(4):565-76. 25220446 10.1016/j.ccr.2014.07.026 F1000 Recommendation
77. Heuts F Rottenberg ME Salamon D: T cells modulate Epstein-Barr virus latency phenotypes during infection of humanized mice. J Virol. 2014;88(6):3235-45. 24390326 10.1128/JVI.02885-13 3957948 F1000 Recommendation